热门资讯> 正文

Calidi Biotherapeutics GAAP每股收益为-1.99美元

2025-08-11 18:22

Calidi Biotherapeutics press release (NYSE:CLDI): Q2 GAAP EPS of -$1.99.
The company had approximately $5.3 million in cash and $0.1 million in restricted cash as of June 30, 2025, compared to $9.6 million in cash and $0.2 million in restricted cash as of December 31, 2024.

More on Calidi Biotherapeutics

Seeking Alpha’s Quant Rating on Calidi Biotherapeutics
Historical earnings data for Calidi Biotherapeutics
Financial information for Calidi Biotherapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。